Sofie Meulewaeter
Gent, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.
Journal: Journal for immunotherapy of cancer
Published: April 05, 2025
Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs.
Journal: Molecular therapy. Methods & clinical development
Published: March 14, 2025
The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs.
Journal: Molecular therapy. Nucleic acids
Published: May 03, 2024
Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: April 05, 2024
Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer.
Journal: Journal of molecular biology
Published: September 15, 2023
Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine.
Journal: Theranostics
Published: April 08, 2023
Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: December 13, 2022
Transport by circulating myeloid cells drives liposomal accumulation in inflamed synovium.
Journal: Nature nanotechnology
Published: March 25, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026